Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Sandoz Is Betting Its Growth on Biosimilars — And the Early Numbers Back It Up

Sandoz's business divides into two segments. Generics, the larger segment, supplies chemically synthesised copies of small-molecule drugs once patents lapse. Biosimilars, smaller but faster-growing, produce close approximations of complex biologic medicines grown in living cells, requiring dedicated manufacturing and clinical comparability studies. Sandoz began …

Ishan Mudgal | 15 July 2026

Oxford Nanopore Has a New CEO and a Concrete Profit Target — Can It Hit 2027?

It designs, manufactures and sells DNA and RNA sequencing platforms — the portable MinION, benchtop GridION and high-throughput PromethION — plus the consumable flow cells, reagent kits and software that generate recurring revenue from the installed base. Spun out of the University of Oxford …

Ishan Mudgal | 15 July 2026

HUTCHMED's Headline Profit Number Isn't What It Looks Like — Here's the Real Picture

A commercial-stage biopharmaceutical company discovering, developing and commercialising targeted therapies and immunotherapies for cancer and immunological diseases. Its scientific base sits in China, with commercial reach extending internationally through licensing partners Takeda and AstraZeneca. Its London quotation is on AIM (not the Main Market) …

Ishan Mudgal | 15 July 2026

CelLBxHealth Rebranded From ANGLE — Now It Has to Prove the New Strategy Works

A medical-diagnostics company in liquid biopsy — analysing tumour-derived material from a blood sample rather than a surgical tissue biopsy. Its Parsortix system is a microfluidic device separating circulating tumour cells (CTCs) largely by size and deformability, an 'epitope-independent' approach that doesn't require tumour …

Ishan Mudgal | 15 July 2026

ECO Animal Health Just Launched Its First Vaccine — After Years of Being a One-Product Company

ECO is a veterinary pharmaceuticals business focused on medicines for pigs and poultry, listed on AIM under EAH. Its defining asset is Aivlosin (also Valosin), a proprietary, patented macrolide antibiotic effective against respiratory and enteric bacterial diseases, particularly mycoplasma infections — distributed across more …

Ishan Mudgal | 15 July 2026

IXICO Doesn't Bet on Any Single Drug — It Sells the Picks and Shovels to Everyone Who Does

When a pharmaceutical sponsor tests a candidate treatment for a condition like Alzheimer's, it needs standardised brain scans collected consistently across many sites, then analysed to extract measurable biomarkers of disease progression or drug effect. IXICO manages that process end to end: recruiting and …

Ishan Mudgal | 15 July 2026

OXB Reinvented Itself as a Contract Manufacturer — And Bristol Myers Squibb Just Signed Up

OXB is a specialist manufacturer of viral vectors — engineered biological carriers that deliver genetic material into cells and underpin many cell and gene therapies. It develops manufacturing processes for biotech and pharmaceutical clients and produces material across clinical and commercial stages, spanning lentiviral …

Ishan Mudgal | 15 July 2026

Oxford BioDynamics's Prostate Test Orders Jumped 126% — But the Cash Clock Is the Real Story

EpiSwitch measures chromosome conformations — how DNA folds inside the nucleus — to identify regulatory signatures associated with disease, arguing these change systemically and early in disease and can be detected in a routine blood sample. Discovery uses a chromosome-conformation-capture approach paired with a …

Ishan Mudgal | 15 July 2026

Poolbeg Pharma's Lead Drug Just Dosed Its First Patient — After a Merger Fell Apart

Poolbeg favours candidates that already carry human clinical data (POLB 001 has prior human exposure from its influenza origins) or use validated technologies. It licenses capability rather than building it — encapsulation technology from AnaBio Technologies for oral GLP-1 work, AI discovery alongside CytoReason …

Ishan Mudgal | 15 July 2026

Animalcare Group's AIM Story Is Ending — In a £235m Private-Equity Deal

A York-based, commercial-stage animal-health company selling veterinary pharmaceuticals through veterinary channels — companion-animal medicines covering pain, dental care and dermatology, alongside a growing equine franchise and production-animal products. Following the January 2025 Randlab acquisition, its reach extends into Australia, New Zealand and the Middle …

Ishan Mudgal | 15 July 2026
Support

Hi! How can we help you today?

Loading…